Stock Performance: Becton, Dickinson & Co (BDX) shares have surpassed the average analyst 12-month target price of $200.40, currently trading at $200.43/share.
Analyst Reactions: Analysts may respond to the stock reaching the target price by either downgrading their valuation or raising their target price, depending on the company's fundamental developments.
Diverse Analyst Targets: Within the Zacks coverage universe, analyst targets for BDX vary significantly, with one as low as $183.00 and another as high as $230.00, indicating a standard deviation of $15.536.
Investor Considerations: The crossing of the average target price signals investors to evaluate whether the stock is on track for further gains or if it’s time to consider selling some shares.
BDX
$195.67+Infinity%1D
Analyst Views on BDX
Wall Street analysts forecast BDX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BDX is 193.71 USD with a low forecast of 183.00 USD and a high forecast of 210.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast BDX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BDX is 193.71 USD with a low forecast of 183.00 USD and a high forecast of 210.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
5 Hold
0 Sell
Moderate Buy
Current: 196.740
Low
183.00
Averages
193.71
High
210.00
Current: 196.740
Low
183.00
Averages
193.71
High
210.00
RBC Capital
Sector Perform
maintain
$202 -> $210
2025-12-17
Reason
RBC Capital
Price Target
$202 -> $210
2025-12-17
maintain
Sector Perform
Reason
RBC Capital raised the firm's price target on Becton Dickinson to $210 from $202 and keeps a Sector Perform rating on the shares as part of a broader research note previewing 2026 for Medical Supplies & Devices. The firm anticipates a year of positive momentum as sector fundamentals are solidly intact driven by the aging demographics, growing global healthcare access, and differentiated innovation, the analyst tells investors in a research note. For the company, RBC believes it is positioned to grow mid-single-digits due to its strong durable core with high recurring revenue.
Morgan Stanley
Patrick Wood
Overweight
maintain
$197 -> $210
2025-12-02
Reason
Morgan Stanley
Patrick Wood
Price Target
$197 -> $210
2025-12-02
maintain
Overweight
Reason
Morgan Stanley analyst Patrick Wood raised the firm's price target on Becton Dickinson to $210 from $197 and keeps an Overweight rating on the shares. Going into 2026, MedTech "looks well-positioned on several fronts" as the firm thinks major product cycles and a supportive hospital spending environment, combined with trough valuations, make for "a solid industry setup," the analyst tells investors in a note for the group on the upcoming year.
Stifel
Buy
downgrade
$224 -> $210
2025-11-07
Reason
Stifel
Price Target
$224 -> $210
2025-11-07
downgrade
Buy
Reason
Stifel lowered the firm's price target on Becton Dickinson to $210 from $224 and keeps a Buy rating on the shares following the company's Q4 report and below-consensus FY26 guidance. This "reset" potentially offers a "conservative setup," the analyst tells investors.
RBC Capital
Shagun Singh
Sector Perform
downgrade
$211 -> $202
2025-11-07
Reason
RBC Capital
Shagun Singh
Price Target
$211 -> $202
2025-11-07
downgrade
Sector Perform
Reason
RBC Capital analyst Shagun Singh lowered the firm's price target on Becton Dickinson to $202 from $211 and keeps a Sector Perform rating on the shares. The company's Q4 results came largely in-line with expectations as it issued preliminary results on 10/15 but delivered a 1% surprise on the bottom-line, the analyst tells investors in a research note. Becton Dickinson's FY26 guidance at low single digit growth was somewhat below consensus due to ongoing headwinds around Alaris comps, China, and vaccine reductions however, the firm added.
About BDX
Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. Its BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. The BD Medical segment consists of various business units, including medication delivery solutions, medication management solutions, advanced monitoring, and pharmaceutical systems. Its BD Life Sciences segment provides products for the collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. Its BD Interventional segment provides vascular, urology, oncology and surgical specialty products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
